Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ZVRA

Zevra Therapeutics Inc

Last Close
Jul 26 • 04:00PM ET
6.22
Dollar change
-0.01
Percentage change
-0.16 		%
Held by: IWM VTI VXF IWO IWN VTWO IWC RSSL DFAS VTWG Scroll to Statements
IndexRUT P/E- EPS (ttm)-1.35 Insider Own0.79% Shs Outstand41.53M Perf Week2.81%
Market Cap260.31M Forward P/E- EPS next Y-0.44 Insider Trans7.13% Shs Float41.52M Perf Month33.76%
Income-50.90M PEG- EPS next Q-0.46 Inst Own33.64% Short Float7.63% Perf Quarter37.61%
Sales28.01M P/S9.29 EPS this Y-14.87% Inst Trans-5.54% Short Ratio10.73 Perf Half Y5.96%
Book/sh1.17 P/B5.33 EPS next Y70.54% ROA-39.48% Short Interest3.17M Perf Year32.06%
Cash/sh1.02 P/C6.07 EPS next 5Y- ROE-84.68% 52W Range3.89 - 7.28 Perf YTD-5.04%
Dividend Est.- P/FCF- EPS past 5Y51.89% ROI-55.02% 52W High-14.56% Beta1.93
Dividend TTM- Quick Ratio2.10 Sales past 5Y44.97% Gross Margin74.96% 52W Low59.90% ATR (14)0.38
Dividend Ex-Date- Current Ratio2.10 EPS Y/Y TTM9.41% Oper. Margin-204.11% RSI (14)62.95 Volatility5.71% 7.94%
Employees69 Debt/Eq0.91 Sales Y/Y TTM198.84% Profit Margin-181.75% Recom1.00 Target Price17.60
Option/ShortYes / Yes LT Debt/Eq0.90 EPS Q/Q-16.55% Payout- Rel Volume2.06 Prev Close6.23
Sales Surprise-8.87% EPS Surprise14.29% Sales Q/Q18.96% EarningsMay 08 BMO Avg Volume295.51K Price6.22
SMA2011.52% SMA5023.67% SMA20018.85% Trades Volume608,316 Change-0.16%
Date Action Analyst Rating Change Price Target Change
Apr-02-24Reiterated Maxim Group Buy $12 → $18
Mar-12-24Initiated William Blair Outperform
Mar-17-23Initiated Maxim Group Buy $12
Jul-10-24 03:04PM
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
(Zacks)
08:24AM
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
(Zacks)
07:48AM
AbbVie names new R&D head; Arcutis eczema cream approved
(BioPharma Dive)
Jul-09-24 03:27PM
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
(Benzinga) +21.94%
09:00AM
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
(GlobeNewswire)
07:30AM Loading…
Jun-25-24 07:30AM
Zevra Therapeutics Expands Executive Leadership Team
(GlobeNewswire)
Jun-18-24 07:30AM
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
(PR Newswire)
Jun-03-24 11:00AM
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
(GlobeNewswire)
May-09-24 12:24PM
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
(Insider Monkey)
07:30AM
Zevra Therapeutics to Participate at Upcoming Investor Events
(GlobeNewswire)
03:03AM
Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 11:57AM
ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024
(InvestorPlace)
09:12AM
Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...
(GuruFocus.com)
08:15AM
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
07:23AM
Zevra Therapeutics: Q1 Earnings Snapshot
(Associated Press Finance)
07:00AM Loading…
07:00AM
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
(GlobeNewswire)
May-01-24 07:30AM
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
(GlobeNewswire)
Apr-29-24 07:30AM
Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
(GlobeNewswire)
Apr-15-24 05:01PM
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
(GlobeNewswire)
Apr-10-24 07:30AM
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
(GlobeNewswire)
Apr-01-24 12:46PM
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
(Insider Monkey) -11.03%
Mar-29-24 12:07PM
Q4 2023 Zevra Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-28-24 09:52PM
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023
(InvestorPlace) -11.03%
06:11PM
Zevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ...
(GuruFocus.com)
04:53PM
Zevra Therapeutics: Q4 Earnings Snapshot
(Associated Press Finance)
04:32PM
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
(GlobeNewswire)
Mar-26-24 04:30PM
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
(GlobeNewswire)
Mar-25-24 04:30PM
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Mar-21-24 10:00AM
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Mar-18-24 07:30AM
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
(GlobeNewswire)
11:56AM Loading…
Mar-07-24 11:56AM
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Mar-04-24 07:30AM
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
(GlobeNewswire) -12.15%
Feb-28-24 07:30AM
Zevra Therapeutics to Participate at Upcoming Investor Conferences
(GlobeNewswire)
Feb-15-24 03:49AM
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
(Zacks) +8.79%
Feb-06-24 07:30AM
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Jan-23-24 07:30AM
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors
(GlobeNewswire)
Jan-08-24 07:30AM
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
(GlobeNewswire) +6.90%
Jan-04-24 08:55AM
Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer
(GlobeNewswire)
Dec-27-23 07:30AM
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
(GlobeNewswire) +10.71%
Nov-20-23 07:30AM
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
(GlobeNewswire)
Nov-12-23 08:42AM
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-07-23 08:17AM
Zevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial Results
(GuruFocus.com)
07:08AM
Zevra Therapeutics: Q3 Earnings Snapshot
(Associated Press Finance)
07:00AM
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results
(GlobeNewswire)
Oct-31-23 07:30AM
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
(GlobeNewswire)
Oct-19-23 07:30AM
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October
(GlobeNewswire)
Oct-10-23 07:30AM
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
(GlobeNewswire)
Oct-05-23 07:30AM
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
(GlobeNewswire)
Oct-02-23 07:30AM
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
(GlobeNewswire)
Sep-20-23 07:30AM
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
(GlobeNewswire)
Sep-09-23 08:00PM
Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023
(GlobeNewswire)
Sep-05-23 07:30AM
Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire) -6.51%
Sep-04-23 09:55AM
How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51%
(Zacks)
Sep-01-23 07:31AM
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
(Zacks) +6.11%
Aug-31-23 12:13PM
Struggling Newton biotech Acer Therapeutics scooped up by Florida firm
(American City Business Journals)
07:30AM
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
(GlobeNewswire)
Aug-19-23 07:40AM
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-17-23 09:55AM
Can Zevra Therapeutics (ZVRA) Climb 227.55% to Reach the Level Wall Street Analysts Expect?
(Zacks)
Aug-15-23 12:15AM
Q2 2023 Zevra Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Aug-14-23 07:42AM
Zevra Therapeutics: Q2 Earnings Snapshot
(AP Finance)
07:30AM
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
(GlobeNewswire)
Aug-07-23 04:45PM
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster
(GlobeNewswire) +7.00%
Aug-02-23 07:30AM
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
(GlobeNewswire)
Jul-19-23 10:30AM
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long
(Simply Wall St.)
07:30AM
Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference
(GlobeNewswire)
Jun-20-23 07:30AM
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
(GlobeNewswire) +6.88%
Jun-13-23 07:30AM
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
(GlobeNewswire)
Jun-03-23 07:30AM
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023
(GlobeNewswire)
May-16-23 06:22AM
Q1 2023 Zevra Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) +7.11%
May-15-23 05:55PM
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
04:59PM
Zevra Therapeutics: Q1 Earnings Snapshot
(AP Finance)
04:05PM
Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results
(GlobeNewswire)
May-10-23 07:30AM
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
(GlobeNewswire)
May-09-23 07:30AM
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
(GlobeNewswire) -9.96%
May-08-23 07:30AM
Zevra Announces Board of Directors and Leadership Changes
(GlobeNewswire)
May-03-23 07:30AM
Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
(GlobeNewswire)
Apr-17-23 04:05PM
Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevras Transformation Strategy
(GlobeNewswire)
06:18AM
Why Investors Shouldn't Be Surprised By Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 31% Share Price Surge
(Simply Wall St.)
Apr-04-23 07:30AM
Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
(GlobeNewswire)
Mar-30-23 07:30AM
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
(GlobeNewswire)
Mar-17-23 07:30AM
Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
(GlobeNewswire)
Mar-15-23 07:26AM
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
(GlobeNewswire) -5.01%
Mar-07-23 07:00AM
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
(GlobeNewswire) -19.44%
Mar-06-23 07:30AM
Zevra Therapeutics to Present at 35th Annual Roth Conference
(GlobeNewswire)
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clifton R. LaDuaneCFO & TreasurerJul 17 '24Buy6.772,00013,54018,469Jul 17 05:54 PM
Anderson ThomasDirectorJul 16 '24Buy6.8110,00068,06520,000Jul 16 04:39 PM
Bode John BDirectorJul 12 '24Buy5.8710,00058,66130,000Jul 15 04:10 PM
Anderson ThomasDirectorSep 06 '23Buy4.8810,00048,76410,000Sep 06 04:39 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 06 '23Buy4.961,0004,95915,309Sep 06 05:11 PM
Bode John BDirectorSep 05 '23Buy5.1310,00051,33320,000Sep 06 04:40 PM
Schafer JoshuaCCO & EVP, Bus. DevelopmentSep 05 '23Buy5.135002,5643,500Sep 06 05:11 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.